Gossamer Bio (GOSS) Exchange Rate Effect (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Exchange Rate Effect of -$101000.0 for Q1 2026, down 196.19% year-over-year from $105000.0 in Q1 2025, and down 5150.0% quarter-over-quarter from $2000.0 in Q4 2025.
Gossamer Bio (GOSS) Exchange Rate Effect (2019 - 2026) Analysis & Trends
Gossamer Bio's Exchange Rate Effect history runs 8 years deep, the most recent figure standing at -$101000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 196.19% year-over-year to -$101000.0; the TTM figure through Mar 2026 stood at -$65000.0 (down 200.0% YoY), while the FY2025 annual figure was $141000.0, up 238.24% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$101000.0, down from $2000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $635000.0 in Q4 2022, with the low at -$533000.0 in Q2 2022.
- The 5-year median for Exchange Rate Effect is -$19000.0 (2023), against an average of -$27588.2.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect slumped 1166.0% in 2022, then surged 1712.5% in 2025.
- Gossamer Bio's Exchange Rate Effect stood at $635000.0 in 2022, then plunged by 69.61% to $193000.0 in 2023, then slumped by 164.77% to -$125000.0 in 2024, then jumped by 101.6% to $2000.0 in 2025, then tumbled by 5150.0% to -$101000.0 in 2026.
- Business Quant data shows GOSS's Exchange Rate Effect at -$101000.0 in Q1 2026, $2000.0 in Q4 2025, and -$95000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Gossamer Bio | 48.48 Mn | -8.54 Mn | - | -12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12,000.00 |
| Jun 30, 2026 | -12,000.00 |
| Mar 31, 2026 | -101,000.00 |
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | -95,000.00 |
| Sep 30, 2025 | -95,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 105,000.00 |
| Mar 31, 2025 | 105,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Mar 31, 2024 | -62,000.00 |